254 related articles for article (PubMed ID: 29872151)
41. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
[TBL] [Abstract][Full Text] [Related]
42. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
Narita Y; Taniguchi H; Komori A; Nitta S; Yamaguchi K; Kondo C; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K
Cancer Chemother Pharmacol; 2014 Feb; 73(2):409-16. PubMed ID: 24322376
[TBL] [Abstract][Full Text] [Related]
43. Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations.
Li W; Qiu T; Ling Y; Guo L; Li L; Ying J
Oncotarget; 2015 Nov; 6(37):39607-13. PubMed ID: 26530529
[TBL] [Abstract][Full Text] [Related]
44. High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection.
Lu Z; Peng J; Wang Z; Pan Z; Yuan Y; Wan D; Li B
Med Oncol; 2016 Nov; 33(11):121. PubMed ID: 27722895
[TBL] [Abstract][Full Text] [Related]
45. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
46. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
47. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278
[TBL] [Abstract][Full Text] [Related]
48. An elevated preoperative serum carbohydrate antigen 19-9 level is a significant predictor for peritoneal dissemination and poor survival in colorectal cancer.
Takakura Y; Ikeda S; Imaoka Y; Urushihara T; Itamoto T
Colorectal Dis; 2015 May; 17(5):417-25. PubMed ID: 25512077
[TBL] [Abstract][Full Text] [Related]
49. Serum CEA and CA 19-9 Levels are Associated with the Presence and Severity of Colorectal Neoplasia.
Kim NH; Lee MY; Park JH; Park DI; Sohn CI; Choi K; Jung YS
Yonsei Med J; 2017 Sep; 58(5):918-924. PubMed ID: 28792134
[TBL] [Abstract][Full Text] [Related]
50. Characteristics of
de la Fouchardière C; Cohen R; Malka D; Guimbaud R; Bourien H; Lièvre A; Cacheux W; Artru P; François E; Gilabert M; Samalin-Scalzi E; Zaanan A; Hautefeuille V; Rousseau B; Senellart H; Coriat R; Flippot R; Desseigne F; Lardy-Cleaud A; Tougeron D
Oncologist; 2019 Dec; 24(12):e1331-e1340. PubMed ID: 31152084
[TBL] [Abstract][Full Text] [Related]
51. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
52. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
53. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
55. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
56. Class 1, 2, and 3
Schirripa M; Biason P; Lonardi S; Pella N; Pino MS; Urbano F; Antoniotti C; Cremolini C; Corallo S; Pietrantonio F; Gelsomino F; Cascinu S; Orlandi A; Munari G; Malapelle U; Saggio S; Fontanini G; Rugge M; Mescoli C; Lazzi S; Reggiani Bonetti L; Lanza G; Dei Tos AP; De Maglio G; Martini M; Bergamo F; Zagonel V; Loupakis F; Fassan M
Clin Cancer Res; 2019 Jul; 25(13):3954-3961. PubMed ID: 30967421
[TBL] [Abstract][Full Text] [Related]
57. The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study.
Yüceyar S; Ertürk S; Dirican A; Cengiz A; Saner H
Int Surg; 1996; 81(2):136-9. PubMed ID: 8912078
[TBL] [Abstract][Full Text] [Related]
58. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
59. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
60. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]